Filter By Category
Archives
Share on -
ACRIXOLIMAB
Generic Name: ACRIXOLIMAB
ABSTRACT -
Acrixolimab is an investigational monoclonal antibody targeting the OX40 ligand (OX40L) pathway, being developed for inflammatory and autoimmune diseases. By blocking OX40L-OX40 interactions, it aims to reduce T-cell activation and downstream inflammatory cascades. It is being studied for conditions such as atopic dermatitis and other chronic inflammatory diseases.
DOSAGE -
Acrixolimab is an investigational biologic. Dosage is defined by ongoing clinical trial protocols. Administered via subcutaneous injection or intravenous infusion depending on trial design. No approved clinical dosage established.
SIDE EFFECTS –
Reported or potential side effects may include:
- Injection site reactions
- Headache
- Fatigue
- Nasopharyngitis
- Upper respiratory tract infections
- Nausea
- Elevated liver enzymes
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Hypersensitivity reactions
- Angioedema
- Urticaria
- Anaphylaxis
- Severe infusion reactions
DRUG INTERACTIONS–
- Live vaccines (contraindicated during therapy)
- Other immunosuppressive agents
- Biologic therapies targeting overlapping pathways
PREAUTIONS–
- Screening for tuberculosis and hepatitis B required before initiation.
- Do not administer live vaccines during treatment.
- Safety in pregnancy not established.
- Monitor for infections during therapy.
- Follow clinical trial monitoring requirements.
WARNINGS –
- Risk of serious infections.
- Immunosuppression may mask signs of infection.
- Not for use as monotherapy in active serious infections.
- Long-term safety data are still being collected.
- Keep out of reach of children.
Share on -
. Developed by